Post

Hepion shelves Phase II NASH trial amid shallow cash resources

Hepion Pharmaceuticals has called it quits on a Phase IIb trial investigating the biotech’s lead drug candidate for the treatment …

Investors advocate for early biotech partnerships for later deal success

Following 2023’s stiff economic environment, companies must prioritise partnerships more than ever in their growth strategies, said Richard Girling, a …

Smaller regulators grasp innovation through international collaboration

Smaller regulatory agencies could introduce more therapies into their national markets through faster regulatory processes, said Dr. Ulf Grawunder, managing …

Targeting mouth cancer with light-activated drugs

With two in five patients with oral cancer dying within five years and 95% of patients requiring life-altering surgery, finding …

EC approves BeiGene’s tislelizumab for three NSCLC indications

BeiGene has announced that its anti-programmed cell death protein 1 (PD-1) monoclonal antibody, tislelizumab, has gained European Commission (EC) approval …